Antares Pharma Provides Update Regarding the Cowen and Company 38th Annual Healthcare Conference
March 13 2018 - 5:45PM
Antares Pharma, Inc. (NASDAQ:ATRS) (the Company) today announced
that due to the blizzard conditions and lack of travel options
present in the greater Boston area, the Company will be unable to
attend the Cowen and Company 38th Annual Healthcare Conference on
Wednesday, March 14, 2018.
This morning, Antares executives provided a
Company update and reviewed fourth quarter and full year 2017
financial results via webcast and conference call. A copy of
the press release can be found on the Antares Pharma website at
www.antarespharma.com, under the “For Investors” section. A
telephone replay of today’s conference call is available until
11:30 a.m. ET on Thursday, April 12, 2018, and can be accessed by
dialing 1-888-203-1112 (US) or 1-719-457-0820 (International) and
entering passcode 6501930. Callers can also access the slide
presentation on the “For Investors” section of the Company’s
website under “Presentations.”
About Antares Pharma
Antares Pharma focuses on self-administered
parenteral pharmaceutical products. The Company’s product, OTREXUP®
(methotrexate) injection for subcutaneous use, is approved in the
U.S. for the treatment of adults with severe active rheumatoid
arthritis, children with active polyarticular juvenile idiopathic
arthritis and adults with severe recalcitrant psoriasis. The
Company’s product Sumatriptan Injection USP, is approved in the
U.S. for the acute treatment of migraine and cluster headache and
is distributed by Teva Pharmaceutical Industries, Ltd. (Teva).
Antares Pharma is also developing an investigational new drug,
XYOSTED™, for the treatment of testosterone deficiency
(hypogonadism). The Company filed a New Drug Application for
XYOSTED™ and received a Complete Response Letter. The
Company's technology platforms include VIBEX® disposable auto
injectors and disposable multi-use pen injectors. Antares Pharma
has license, development and supply agreements with Teva that
include VIBEX® epinephrine, exenatide multi-dose pen, and
teriparatide multi-dose pen. The Company also provides AMAG
Pharmaceuticals with a subcutaneous QuickShot® auto injector for
administering Makena® (hydroxyprogesterone
caproate injection). For more information, visit
www.antarespharma.com.
SAFE HARBOR STATEMENT UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are subject to certain risks
and uncertainties that can cause actual results to differ
materially from those described. Factors that may cause such
differences include, but are not limited to: the timing of the
commercial launch of the Makena subcutaneous auto injector product
in the U.S. and future market acceptance and revenue from the same
; the outcome of the Type A meeting with the U.S. Food and Drug
Administration (FDA) for XYOSTED, the Company’s ability to resolve
the deficiencies identified by the FDA in the Complete Response
Letter for XYOSTED, the timeframe associated with such resolution
and whether any such response will be accepted by the FDA,
FDA approval of the Company’s NDA for XYOSTED and future
market acceptance and revenue for XYOSTED;
successful completion of the transaction with Ferring
International Center, S.A. and satisfaction of the various
conditions in the Ferring asset purchase agreement and payment of
the full purchase price; Teva’s expectations about timing and
approval of the VIBEX® epinephrine pen ANDA by the FDA and
potential product launch of the same, the therapeutic equivalence
rating thereof, and any future revenue from the same; FDA action
with respect to Teva’s Abbreviated New Drug Application (“ANDA”)
for the Teriparatide multi-dose pen and the timing and approval, if
any, by the FDA of the same; FDA action with respect to Teva’s ANDA
for the Exenatide pen and the timing and approval, if any, by the
FDA of the same; Teva’s ability to successfully commercialize
VIBEX® Sumatriptan Injection USP and the amount of revenue from the
same; continued growth of prescriptions and sales of
OTREXUP®; the timing and results of research projects,
clinical trials, and product candidates in development;
actions by the FDA or other regulatory agencies with the respect to
the Company’s products or product candidates of its partners;
continued growth in product, development, licensing and royalty
revenue; the Company’s ability to obtain financial and other
resources for its research, development, clinical, and commercial
activities and other statements regarding matters that are not
historical facts, and involve predictions. These statements involve
known and unknown risks, uncertainties and other factors that may
cause actual results, performance, achievements or prospects to be
materially different from any future results, performance,
achievements or prospects expressed in or implied by such
forward-looking statements. In some cases you can identify
forward-looking statements by terminology such as ''may'',
''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'',
''anticipate'', ''believe'', ''estimate'', ''predict'',
''potential'', ''seem'', ''seek'', ''future'', ''continue'', or
''appear'' or the negative of these terms or similar expressions,
although not all forward-looking statements contain these
identifying words. Additional information concerning these and
other factors that may cause actual results to differ materially
from those anticipated in the forward-looking statements is
contained in the "Risk Factors" section of the Company's Annual
Report on Form 10-K, and in the Company's other periodic reports
and filings with the Securities and Exchange Commission. The
Company cautions investors not to place undue reliance on the
forward-looking statements contained in this press release. All
forward-looking statements are based on information currently
available to the Company on the date hereof, and the Company
undertakes no obligation to revise or update these forward-looking
statements to reflect events or circumstances after the date of
this press release, except as required by law.
Contact:
Jack HowarthVice President, Corporate
Affairs609-359-3016jhowarth@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Apr 2023 to Apr 2024